Last $9.65 USD
Change Today +0.30 / 3.21%
Volume 500.0
As of 10:00 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

adma biologics inc (ADMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $14.00
52 Week Low
04/30/14 - $6.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADMA BIOLOGICS INC (ADMA)

Related News

No related news articles were found.

adma biologics inc (ADMA) Related Businessweek News

No Related Businessweek News Found

adma biologics inc (ADMA) Details

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

42 Employees
Last Reported Date: 03/28/14
Founded in 2004

adma biologics inc (ADMA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $484.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $343.9K
Chief Scientific & Medical Officer and Execut...
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

adma biologics inc (ADMA) Key Developments

ADMA Biologics, Inc. Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference

ADMA Biologics, Inc. announced positive results on the primary and secondary endpoint evaluations from its pivotal Phase III trial for RI-002 in Primary Immune Deficiency Disease (PIDD) in a poster presentation at the American Academy of Allergy, Asthma and Immunology Annual Meeting. In December 2014, the company announced that the trial met its primary endpoint with zero serious bacterial infections (SBI). In this multi-site study of 59 patients diagnosed with PIDD, investigators reported on the secondary endpoints that included: a total of 93 days, or 1.66 days per patient per year lost from work or school due to infection; one hospitalization due to an infection of only five days duration in the entire study and IgG trough levels above those required by the FDA for IVIG products. Additionally, there was a marked increase in all of the measured specific anti-pathogen antibodies in PK subjects (n=31), with the great increase, 5.3 fold, seen in the level of neutralizing antibody titers to RSV. The safety profile of RI-002 was comparable to that of other immunoglobulins. These encouraging secondary end point results follow the prior announcement that the trial achieved its primary endpoint with zero reported acute serious bacterial infections (SBI) in the course of the trial.

ADMA Biologics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM

ADMA Biologics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Adam S. Grossmann, Founder, Chief Executive Officer, President and Director.

ADMA Biologics Receives $5 million Tranche from Hercules Technology Growth Capital

ADMA Biologics, Inc. announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMA:US $9.65 USD +0.30

ADMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.2x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMA BIOLOGICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at